Luke A Masterson

发表

Improved physical stability of an Antibody Drug Conjugate using Host-Guest chemistry.

C. F. van der Walle, M. L. Greco, P. Ravn, 2019, Bioconjugate chemistry.

Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach.

J. Subramony, P. Tyagi, S. Mao, 2019, Journal of pharmaceutical sciences.

Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.

Jeffrey T. Lau, BinQing Wei, S. Spencer, 2017, Journal of medicinal chemistry.

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers

Jeffrey T. Lau, S. Spencer, P. Polakis, 2017, Molecular Cancer Therapeutics.

Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates.

Herren Wu, P. Thompson, Changshou Gao, 2016, ACS medicinal chemistry letters.

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

P. Burke, P. Senter, D. Sussman, 2013, Bioconjugate chemistry.

Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers.

J. Hartley, D. Schiavone, M. Snaith, 2019, European journal of medicinal chemistry.

Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer

Herren Wu, Vanessa M Muniz-Medina, Changshou Gao, 2019, mAbs.

An optimised synthesis of SG3376, a non-cleavable antibody-drug conjugate pyrrolobenzodiazepine drug-linker

Gary C. Kemp, A. Tiberghien, P. Howard, 2017 .

Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates

M. Rebelatto, P. Ryan, N. Dimasi, 2017, Clinical Cancer Research.

Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.

R. Begent, V. Spanswick, J. Hartley, 2006, Bioorganic & medicinal chemistry letters.

SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

C. Fegan, J. Hartley, M. Suggitt, 2010, Cancer research.

Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate.

J. Hartley, Zhizhi Chen, A. Tiberghien, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) C8 cyclic amine conjugates.

T. C. Jenkins, S. J. Croker, P. Howard, 2004, Bioorganic & medicinal chemistry letters.

Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.

J. Hartley, David G. Williams, A. Tiberghien, 2016, ACS medicinal chemistry letters.

Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

J. Hartley, P. V. van Berkel, S. Mao, 2018, Scientific Reports.

Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus

J. Hartley, A. Brentnall, J. Marshall, 2020, Theranostics.

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

P. Parren, A. Akarca, T. Marafioti, 2016, Molecular Cancer Therapeutics.

Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.

S. Steinbacher, BinQing Wei, C. Eigenbrot, 2017, Journal of medicinal chemistry.

SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

M. Rebelatto, S. Sridhar, K. Papadopoulos, 2018, Clinical Cancer Research.

Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

R. Chaerkady, M. Cobbold, Herren Wu, 2021, Molecular Cancer Therapeutics.

Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.

Herren Wu, Herren Wu, Changshou Gao, 2018, Bioorganic & medicinal chemistry letters.

Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

J. Hartley, P. V. van Berkel, S. Mao, 2018, Scientific Reports.

Potentiation of PBD dimers by lipophilicity manipulation.

J. Hartley, S. Mao, Jay Harper, 2019, Current topics in medicinal chemistry.

Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates.

M. Waring, C. Laughton, P. Loadman, 2006, Journal of Medicinal Chemistry.

Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.

M. Marelli, J. Hartley, P. Thompson, 2015, Bioconjugate chemistry.

Engineered Ultrasmall Nanoparticle Drug‐Immune Conjugates with “Hit and Run” Tumor Delivery to Eradicate Gastric Cancer

F. Chen, M. Marelli, R. Christie, 2022, Advanced therapeutics.

CHAPTER 14. Pyrrolobenzodiazepine Dimers as Antibody–Drug Conjugate (ADC) Payloads

A. Tiberghien, P. Howard, S. Gregson, 2019, Cytotoxic Payloads for Antibody–Drug Conjugates.

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

M. Albertella, Z. Cooper, R. Christie, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

P. Burke, P. Senter, D. Sussman, 2013, Bioconjugate chemistry.

SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

C. Fegan, J. Hartley, M. Suggitt, 2010, Cancer research.